Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055560 · ClinicalTrials.gov registry record
Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients
A clinical trial, sponsored by Saladax Biomedical.
- Completed
- Registry status
- 146
- Enrollment target
NCT02055560 is a clinical trial that has completed, run by Saladax Biomedical. The registered enrollment target is 146 participants.
The verdict
NCT02055560 has completed, sponsored by Saladax Biomedical.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate whether the management of colorectal cancer (CRC) patients with 5-fluorouracil (5-FU) exposure optimization testing reduces 5-FU related toxicities and improves outcomes compared to the current standard of care. A secondary objective is to characterize the variability of 5-FU levels among CRC patients managed with 5-FU exposure optimization testing and the impact of such management on 5-FU plasma levels and drug doses during the course of chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-12-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02055560
The ClinicalTrials.gov registry entry for NCT02055560 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saladax Biomedical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02055560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02055560 about?
NCT02055560 is a clinical study titled "Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients". The primary objective of this study is to evaluate whether the management of colorectal cancer (CRC) patients with 5-fluorouracil (5-FU) exposure optimization testing reduces 5-FU related toxicities and improves outcomes compared to the current standard of care. A secondary objective is to character...
What is the current status of trial NCT02055560?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2014-01. Estimated completion is 2015-12-18.
Who is sponsoring clinical trial NCT02055560?
This trial is sponsored by Saladax Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.